EC Number   |
Protein Variants |
Reference |
|---|
   3.4.24.B11 | E385A |
catalytically inactive zinc-binding site mutant of ADAMTS1 |
669469 |
| 3.4.24.B11 | E385A |
inactive |
679491 |
| 3.4.24.B11 | E385A |
point mutation in the zinc binding domain results in an inactive mutant enzyme form |
649597 |
| 3.4.24.B11 | E385A |
point mutation in the zinc binding domain, catalytically inactive mutant |
649329 |
| 3.4.24.B11 | E386Q |
oligonucleotide primer mutagenesis, mutation within the zinc binding motif, inactive |
651268 |
| 3.4.24.B11 | E386Q |
oligonucleotide primer mutagenesis, mutation within the zinc binding motif, loss of zinc-binding capacity, loss of activity and capacity to complex with alpha2-macroglobulin |
651928 |
| 3.4.24.B11 | more |
construction of soluble C-terminal deletion mutants |
651268 |
| 3.4.24.B11 | more |
construction of soluble C-terminal deletion mutants, that are still able to form complexes with alpha2-macroglobulin |
651928 |
| 3.4.24.B11 | more |
induction of tumor growth in nude mice by injection of carcinoma cells, cell line T47D expressing the recombinant His-Myc-tagged wild-type or mutant E385A enzyme, number and distribution of vessels in the tumors are reduced compared to control tumors, high degree of edema and necrosis, the truncated construct comprising the amino acid residues 549-951 had no effect on tumor growth, but the isolated first TSP1 repeat does |
649329 |
| 3.4.24.B11 | more |
introduction of a KpnI site at the 5'-end, expression in carcinoma cell line T47D |
652409 |
